Stage IV Colorectal Cancer Patients with High Risk Mutation Profiles Survived 16 Months Longer with Individualized...

Area of Science:

• Oncology
• Genomics
• Clinical Research

Background:

• The debate between personalized treatment and standard of care in clinical practice is ongoing.
• Understanding factors influencing survival in metastatic colorectal cancer (mCRC) is crucial.

Purpose of the Study:

• To investigate if tumor mutation profiles or real-world treatment differences explain survival disparities in mCRC patients.
• To compare the efficacy of individualized treatment versus standard of care in high-risk mCRC patients.

Main Methods:

• Retrospective study of 108 mCRC patients (54 American, 54 German) of European ancestry.
• Tumor mutation profiles, tumor mutation burden, and microsatellite status analyzed using FoundationOne or IDT Pan-Cancer assays.
• High-risk patients identified using Schell's mutational classification.

Main Results:

• High-risk patients receiving individualized treatment survived a median of 16 months longer than those on standard of care (p < 0.001).
• Tumor mutation profiles, not country of origin, stratified patients into distinct risk groups.
• No significant difference in tumor mutation landscape observed between American and German patients.

Conclusions:

• Individualized treatment approaches significantly enhance survival for high-risk mCRC patients after standard care options are exhausted.
• Congruent tumor mutation landscapes across populations support transatlantic collaboration and harmonization of treatment guidelines.